New style Type A 100units Allergan Botulinum Toxin For facial wrinkles

New style Type A 100units Allergan Botulinum Toxin For facial wrinkles

Allergan Botulinum Toxin overview

The first type of introduced to the market was onabotulinum toxin A. In 2002, it was recommended to be used as a cosmetic treatment for glabellar frown lines by the Food and Drug Administration (FDA). The second formulation of onabotulinum toxin A, which was produced in France, obtained its license to be used for esthetic purposes from the European Union in 2006 and was approved by the FDA in 2009.5, type A has become a term used by the society to describe all ingredients used in cosmetic treatments.

A study reported the effectiveness of Type A for reducing the appearance of facial wrinkles; since then, it has been used as a cosmetic treatment. injections can be used to treat glabellar frown lines, wrinkles around the lips (smoker’s lines) and marionette lines, platysmal bands in the neck, strabismus, blepharospasm, cervical dystonia, hyperhidrosis as well as synkinesis following facial surgery.

Allergan Mechanism of action

The mechanism of action of includes the following four main steps:

The first step is binding of the toxin to specific receptors on the surface of the presynaptic cells, mediated by the C-terminal of the heavy chain. This step occurs over approximately 30 mins.

The second step is internalization, which is an energy-dependent receptor-mediated endocytic process. In this step, the plasma membrane of nerve cells invaginates around the toxin-receptor complex, forming a vesicle containing a toxin in nerve terminal.

The third step is translocation. Following internalization, the disulfide bond is cleaved and the 50-kDa light chain of the toxin is released across the endosomal membrane of the endocytic vesicle into the cytoplasm of the nerve terminal.

The last step is blocking. The light chain of serotypes A and E inhibit the release of acetylcholine by cleaving the cytoplasmic protein (SNAP-25) needed for the docking of acetylcholine vesicles on the inner side of the nerve membrane of the nerve terminal.

Following the injection, the toxin diffuses into the tissue until it binds selectively and reversibly in the presynaptic terminal of the neuromuscular junction and then attaches to the specific protein-membrane responsible for acetylcholine excretion. The toxin immediately inhibits the release of acetylcholine in the neuromuscular junction causing relaxation of local muscles that is reversible, resulting in reduced facial wrinkles/lines, of which some are due to constant facial muscle contractions.

Allergan photos

Allergan Parameter

Before and And After

Packing And Delivery